educating doctors, helping patients
educating doctors, helping patients
educating doctors, helping patients
educating doctors, helping patients
educating doctors, helping patients
categories
categories
categories
categories
categories
Pharmaceutical / B2B2C / Brand Identity / Website / Thought Leadership Content
Pharmaceutical / B2B2C / Brand Identity / Website / Thought Leadership Content
Pharmaceutical / B2B2C / Brand Identity / Website / Thought Leadership Content
Pharmaceutical / B2B2C / Brand Identity / Website / Thought Leadership Content
Pharmaceutical / B2B2C / Brand Identity / Website / Thought Leadership Content
mission
mission
mission
mission
mission
Engage and educate multiple audiences about unmet needs for the 36 million people in the U.S. living with migraine; Colucid’s novel approach to pharmaceutical therapy and clinical trials focusing on patients who have cardiovascular disease risk factors.
Engage and educate multiple audiences about unmet needs for the 36 million people in the U.S. living with migraine; Colucid’s novel approach to pharmaceutical therapy and clinical trials focusing on patients who have cardiovascular disease risk factors.
Engage and educate multiple audiences about unmet needs for the 36 million people in the U.S. living with migraine; Colucid’s novel approach to pharmaceutical therapy and clinical trials focusing on patients who have cardiovascular disease risk factors.
Engage and educate multiple audiences about unmet needs for the 36 million people in the U.S. living with migraine; Colucid’s novel approach to pharmaceutical therapy and clinical trials focusing on patients who have cardiovascular disease risk factors.
Engage and educate multiple audiences about unmet needs for the 36 million people in the U.S. living with migraine; Colucid’s novel approach to pharmaceutical therapy and clinical trials focusing on patients who have cardiovascular disease risk factors.
approach
approach
approach
approach
approach
To effectively address specific audience education needs we created an expert advisory board to help distill proprietary research into digestible, informative content for each audience. This content formed the basis for separate knowledge pathways that informed navigation and user experience on the new website. Each audience could access relevant content including articles, infographics, checklists, presentations and clinical results to help them learn about Colucid’s therapy and novel approach to treating migraines, and what they needed to know about current migraine research.
To effectively address specific audience education needs we created an expert advisory board to help distill proprietary research into digestible, informative content for each audience. This content formed the basis for separate knowledge pathways that informed navigation and user experience on the new website. Each audience could access relevant content including articles, infographics, checklists, presentations and clinical results to help them learn about Colucid’s therapy and novel approach to treating migraines, and what they needed to know about current migraine research.
To effectively address specific audience education needs we created an expert advisory board to help distill proprietary research into digestible, informative content for each audience. This content formed the basis for separate knowledge pathways that informed navigation and user experience on the new website. Each audience could access relevant content including articles, infographics, checklists, presentations and clinical results to help them learn about Colucid’s therapy and novel approach to treating migraines, and what they needed to know about current migraine research.
To effectively address specific audience education needs we created an expert advisory board to help distill proprietary research into digestible, informative content for each audience. This content formed the basis for separate knowledge pathways that informed navigation and user experience on the new website. Each audience could access relevant content including articles, infographics, checklists, presentations and clinical results to help them learn about Colucid’s therapy and novel approach to treating migraines, and what they needed to know about current migraine research.
To effectively address specific audience education needs we created an expert advisory board to help distill proprietary research into digestible, informative content for each audience. This content formed the basis for separate knowledge pathways that informed navigation and user experience on the new website. Each audience could access relevant content including articles, infographics, checklists, presentations and clinical results to help them learn about Colucid’s therapy and novel approach to treating migraines, and what they needed to know about current migraine research.
impact
impact
impact
impact
impact
The new website provided relevant content for each audience to empower physicians and patients to better diagnose the disease and identify opportunities for those with cardiovascular risk.
Both content and website provided a stronger brand presence and identity for investors and medical influencers to understand the potential for Colucid and its novel drug Lasmitidan.
Colucid was acquired in spring 2018 by Eli Lilly for $1B.
The new website provided relevant content for each audience to empower physicians and patients to better diagnose the disease and identify opportunities for those with cardiovascular risk.
Both content and website provided a stronger brand presence and identity for investors and medical influencers to understand the potential for Colucid and its novel drug Lasmitidan.
Colucid was acquired in spring 2018 by Eli Lilly for $1B.
The new website provided relevant content for each audience to empower physicians and patients to better diagnose the disease and identify opportunities for those with cardiovascular risk.
Both content and website provided a stronger brand presence and identity for investors and medical influencers to understand the potential for Colucid and its novel drug Lasmitidan.
Colucid was acquired in spring 2018 by Eli Lilly for $1B.
The new website provided relevant content for each audience to empower physicians and patients to better diagnose the disease and identify opportunities for those with cardiovascular risk.
Both content and website provided a stronger brand presence and identity for investors and medical influencers to understand the potential for Colucid and its novel drug Lasmitidan.
Colucid was acquired in spring 2018 by Eli Lilly for $1B.
The new website provided relevant content for each audience to empower physicians and patients to better diagnose the disease and identify opportunities for those with cardiovascular risk.
Both content and website provided a stronger brand presence and identity for investors and medical influencers to understand the potential for Colucid and its novel drug Lasmitidan.
Colucid was acquired in spring 2018 by Eli Lilly for $1B.
CHECK OUT THE BIG WAVES WE'VE MADE FOR THESE OTHER BRANDS
CHECK OUT THE BIG WAVES WE'VE MADE FOR THESE OTHER BRANDS
CHECK OUT THE BIG WAVES WE'VE MADE FOR THESE OTHER BRANDS
CHECK OUT THE BIG WAVES WE'VE MADE FOR THESE OTHER BRANDS
CHECK OUT THE BIG WAVES WE'VE MADE FOR THESE OTHER BRANDS
REACH OUT
Cam Brown, CEO
978-832-1410
cbrown@kingfishmedia.com
REACH OUT
Cam Brown, CEO
978-832-1410
cbrown@kingfishmedia.com
REACH OUT
Cam Brown, CEO
978-832-1410
cbrown@kingfishmedia.com
REACH OUT
Cam Brown, CEO
978-832-1410
cbrown@kingfishmedia.com
REACH OUT
Cam Brown, CEO
978-832-1410
cbrown@kingfishmedia.com
LET'S MAKE WAVES
LET'S MAKE WAVES
LET'S MAKE WAVES
LET'S MAKE WAVES
LET'S MAKE WAVES